BioSpace News Archive

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited product sales results for the year ended December 31, 2019.

Tampa-based Savii, Inc., is delighted to announce a formal partnership with industry leading healthcare consulting firm, Maxwell Healthcare Associates.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their upcoming webinar, “Model-Based Approach to Design Bispecific Modalities in Early Discovery” occurs Tuesday, February 4, 2020 at 2p.m. ET / 11a.m. PT.

Ergomed plc (LSE: ERGO) (“Ergomed” or the “Company”), a company focused on providing specialised services to the pharmaceutical industry, announced the appointment of Lewis Cameron as Chief Operating Officer (COO) and to the Board.

Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that Egan-Jones Proxy Services (“Egan-Jones”) has recommended shareholders vote for both HDF nominees on the Blue proxy card.

In a release issued earlier under the same headline by Pacific Biosciences of California, Inc., please note that the date in paragraph three should read February 6, 2020, not January 6, 2020, as previously stated.

Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis).

For the sixth consecutive year, Astellas has achieved a perfect score on the Human Rights Campaign Foundation’s annual Corporate Equality Index.

Sol-Gel Technologies Ltd. announced the presentation of results from the Company’s Phase 3 trials for its candidates Epsolay® for the treatment of moderate-to-severe papulopustular rosacea and Twyneo® for the treatment of moderate-to-severe acne vulgaris.

Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that it has commenced an underwritten public offering of $325,000,000 in shares of its common stock.